A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Status:
RECRUITING
Trial end date:
2029-03-31
Target enrollment:
Participant gender:
Summary
This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is being given.